CYTH3抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P02588(CYTH3 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The CYTH3 antibody targets the CYTH3 protein, a member of the cytohesin/ARNO family of guanine nucleotide exchange factors (GEFs). CYTH3. also known as ARNO3 or GRP1. is characterized by a central Sec7 domain that catalyzes GTP-GDP exchange on ADP-ribosylation factor (ARF) proteins, regulating vesicular trafficking, cytoskeletal reorganization, and cellular signaling. It plays a role in processes like endocytosis, receptor recycling, and insulin signaling, particularly through interactions with ARF6. CYTH3 is expressed in various tissues, including immune cells, the pancreas, and the brain, and its dysregulation has been linked to cancer metastasis, neurological disorders, and metabolic diseases.

CYTH3 antibodies are widely used in research to study the protein's expression, localization, and function. They enable detection via techniques like Western blotting, immunofluorescence, and immunohistochemistry. Studies utilizing these antibodies have revealed CYTH3's involvement in tumor cell invasion, synaptic plasticity, and glucose homeostasis. In cancer, elevated CYTH3 levels correlate with enhanced cell migration and poor prognosis, suggesting its potential as a therapeutic target. The antibody also aids in exploring CYTH3's interplay with signaling pathways, such as PI3K/AKT and EGFR, providing insights into mechanisms underlying disease progression. Commercial CYTH3 antibodies are typically validated for specificity and sensitivity, ensuring reliability in both diagnostic and experimental contexts.